Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company has already embarked upon significant expansion in Turkey
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
